Skip to content

Neuroplasticity: all studies

Page 23 of 178: studies 221 to 230 of 1,772, newest first. Back to the neuroplasticity overview

Research

[Anxiety-like behaviors induced by chronic administration of the synthetic cannabinoid 4F-ABUTINACA in rats and the underlying mechanisms].

Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences September 25, 2026 Baobao Shi, Haitao Wang, Wenhua Zhou et al.

To elucidate the Δ9-tetrahydrocannabinol (THC)-like discrimina-tive stimulus effects of 4F-ABUTINACA and to investigate the potential mechanisms underlying anxiety-like behaviors induced by chronic 4F-ABUTINACA administration. A THC drug discrimination procedure was employed in six adult male Sprague-Dawley rats to assess the THC-like discriminative stimulus effects of 4F-ABUTINACA and to...

Ketamine-enhanced psychotherapy for smoking cessation: A pilot study of feasibility, safety, and clinical outcomes.

Journal of Psychopharmacology September 25, 2026 Jennifer Jones, Joseph Redding, Emily Amador

Tobacco use remains a leading preventable cause of morbidity and mortality. Although several pharmacotherapies and behavioral treatments for tobacco use disorder (TUD) exist, their overall efficacy is modest, underscoring the need for innovative treatment approaches. Ketamine, a rapid-acting glutamate receptor antagonist with neuroplasticity-enhancing properties, has shown promise in the...

Therapeutic potential of classic and non-classic psychedelics in neurodevelopmental disorders: Opportunities and challenges

Pharmacological Research August 26, 2026 Mattia Giovenzana, Noemi Nicosia, Stefano Spinosa et al.

Neurodevelopmental disorders (NDDs) comprise a heterogeneous group of conditions arising from altered brain development and leading to impairments in social, cognitive, emotional, and motor domains. Clinical manifestations are highly variable in severity and symptom profile, reflecting the complex and multifactorial etiology of NDDs. Available treatments are limited to early behavioral...

From network destabilisation to adaptive reconfiguration: A hippocampal longitudinal axis model of psychedelic therapy.

Progress in Neuro-Psychopharmacology and Biological Psychiatry August 20, 2026 Charalampos L. Kandilakis, Costas Papatheodoropoulos

Psychedelic-assisted therapy has emerged as a promising therapeutic approach across several psychiatric disorders, yet the mechanisms linking acute brain-state changes and subjective experience to sustained clinical improvement remain incompletely understood. Here, we extend a previously proposed excitation/inhibition (E/I)-centred dual-phase model of psychedelic action to the therapeutic...

Experience, plasticity, and context: Beyond single-level models of antidepressant action.

Journal of Psychopharmacology August 17, 2026 David Eckert

The re-emergence of serotonergic psychedelics has introduced rapid-acting antidepressant effects and has been widely described as a paradigmatic shift in depression treatment. Recently, there has been intense debate about whether the acute subjective effects of psychedelics are necessary for their therapeutic efficacy or merely byproducts of underlying neuroplastic processes. Recent...

[(Es)ketamine: practice update].

Der Nervenarzt August 17, 2026 Stefan Vestring, Katharina Domschke, Claus Normann

Ketamine has been established as an anesthetic agent for decades. Around the turn of the millennium initial clinical studies demonstrated that subanesthetic doses of ketamine can exert antidepressant effects in treatment-resistant depression. These findings established the concept of an effective glutamatergic antidepressant treatment and initiated a paradigm shift. For many years, intravenous...

Classic psychedelics and autism spectrum disorder: preclinical evidence, mechanistic insights and unresolved challenges.

Neuroscience & Biobehavioral Reviews August 1, 2026 Fabrizio Ascone, Diletta Giangiacomo, Viviana Trezza

Classic psychedelics have re-emerged as compelling probes of neural plasticity, raising interest in their potential relevance for behavioral and circuit-level features associated with autism spectrum disorder (ASD). Although only a limited number of studies have examined these compounds in validated animal models of ASD, a growing body of preclinical work has investigated their effects on...

DOI: 10.1016/j.neubiorev.2026.106761 (opens in new tab) Full text (opens in new tab) Synaptic plasticity 5-ht2a signaling Autism spectrum disorder Classic psychedelics +2

Network dysregulation in depression: A synthesis of HPA Axis, BDNF signaling, and neurotransmitter interactions across multidimensional systems.

Pharmacology, Biochemistry, and Behavior August 1, 2026 Mengyang He, Zhifei Shi, Ruijie Zhan et al.

Depression is a complex mental disorder threatening global public health. Its pathophysiological mechanisms involve multidimensional dysfunctions including the emotional-cognitive circuit, Hypothalamic-Pituitary-Adrenal (HPA) axis, neurotransmitter systems and neuroplasticity. Current studies mostly analyze each system in isolation, lacking a unified integrated framework. This review proposes...

Psychedelic drug action at dendrites is gated by behavioral state and serotonin receptors

bioRxiv (Cold Spring Harbor Laboratory) July 20, 2026 Neil K. Savalia, Ling-Xiao Shao, Cory A. Knox et al. preprint

SUMMARY How psychedelics act on cortical dendrites to produce long-lasting structural plasticity remains poorly understood. Here, we characterize the effects of psilocybin on dendritic calcium dynamics in pyramidal tract neurons of the mouse medial frontal cortex. Psilocybin transiently increases calcium event rates in apical dendritic tufts over a time course that parallels the drug’s...

Beyond Monoamines: Ketamine, Esketamine, and Classic Psychedelics in the Treatment of Depression

Zenodo (CERN European Organization for Nuclear Research) July 17, 2026 Bartosz Niciński, Magdalena Kloc, Ewa Wiench, Natasza Millan, Aleksandra Blicharz, Wojciech Kozdraś, Lidia Kozaczko, Gabriela Szewczyk, Elżbieta Bukowczan, Alicja Zając, Damian Broda, Alicja Benecka preprint

Major depressive disorder is a highly burdensome psychiatric condition worldwide, and many patients do not achieve full remission after standard monoaminergic antidepressant treatment. This has contributed to growing interest in rapid-acting antidepressant interventionstargeting neurobiological pathways beyond traditional serotonin, norepinephrine, and dopamine mechanisms. This review...